KTOV Kitov Pharma Ltd.

0.75
+0.06  (+9%)
Previous Close 0.69
Open 0.74
Price To Book 1.34
Market Cap 14,645,546
Shares 19,529,999
Volume 1,982,147
Short Ratio
Av. Daily Volume 141,281

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced May 31, 2018.
KIT-302
Osteoarthritis and Hypertension
Phase 1/2 IND to be filed 2H 2019.
NT-219
Squamous cell carcinoma of the head & neck (SCCHN)
Phase 1/2 trial to commence 1H 2020.
CM-24 and Opdivo

Latest News

  1. Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal
  2. Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority
  3. Kitov Pharma Reports First Half 2019 Financial Results and Provides Business Update
  4. Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements
  5. Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancers
  6. Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi™
  7. Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference
  8. Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack
  9. Kitov Announces Key Milestone in FameWave Acquisition
  10. FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)
  11. Potential Milestones Coming for Kitov Pharma and Product Commercialization Plans
  12. These Four Healthcare Stocks Could Test March Highs
  13. Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company
  14. Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update
  15. A Biotech Play You Can't Afford To Miss
  16. Kitov Closes $6 Million Registered Direct Offering
  17. Small Caps Soaring Off of Bottoms
  18. Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
  19. Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
  20. Kitov Announces Pricing of $6 Million Registered Direct Offering